The Application of Quality Risk Management to the Bacterial Endotoxins Test: Use of Hazard Analysis and Critical Control Points

Risk analysis is widely used in the pharmaceutical industry to manage production processes, validation activities, training, and other activities. Several methods of risk analysis are available (for example, failure mode and effects analysis, fault tree analysis), and one or more should be chosen and adapted to the specific field where they will be applied. Among the methods available, hazard analysis and critical control points (HACCP) is a methodology that has been applied since the 1960s, and whose areas of application have expanded over time from food to the pharmaceutical industry. It can be easily and successfully applied to several processes because its main feature is the identification, assessment, and control of hazards. It can be also integrated with other tools, such as fishbone diagram and flowcharting. The aim of this article is to show how HACCP can be used to manage an analytical process, propose how to conduct the necessary steps, and provide data templates necessary to document and useful to follow current good manufacturing practices. LAY ABSTRACT: In the quality control process, risk analysis is a useful tool for enhancing the uniformity of technical choices and their documented rationale. Accordingly, it allows for more effective and economical laboratory management, is capable of increasing the reliability of analytical results, and enables auditors and authorities to better understand choices that have been made. The aim of this article is to show how hazard analysis and critical control points can be used to manage bacterial endotoxins testing and other analytical processes in a formal, clear, and detailed manner.

[1]  J. Agalloco,et al.  Risk analysis for aseptic processing : The Akers-Agalloco method , 2005 .

[2]  Nicolas Martelli,et al.  The application of hazard analysis and critical control points and risk management in the preparation of anti-cancer drugs. , 2009, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[3]  James Agalloco Importance of Background Microbial Levels in the Manufacture and Testing of Sterile Products , 2005 .

[4]  Hartmut F Zimmermann,et al.  Proposal on How To Conduct a Biopharmaceutical Process Failure Mode and Effect Analysis (FMEA) as a Risk Assessment Tool , 2011, PDA Journal of Pharmaceutical Science and Technology.

[5]  Bernard McGarvey,et al.  Quantitative risk modeling in aseptic manufacture. , 2006, PDA journal of pharmaceutical science and technology.

[6]  D M Barends,et al.  Risk analysis by FMEA as an element of analytical validation. , 2009, Journal of pharmaceutical and biomedical analysis.

[7]  J. Samet,et al.  From the Food and Drug Administration. , 2002, JAMA.

[8]  W. Whyte,et al.  A cleanroom contamination control system , 2002 .

[9]  Jatinder Singh International conference on harmonization of technical requirements for registration of pharmaceuticals for human use , 2015, Journal of pharmacology & pharmacotherapeutics.

[10]  J. Jorgensen,et al.  Endotoxins : Pyrogens, LAL Testing and Depyrogenation , 2001 .

[11]  Klaus-Dieter Kühn,et al.  Use of the hazard analysis and critical control points (HACCP) risk assessment on a medical device for parenteral application. , 2003, PDA journal of pharmaceutical science and technology.

[12]  J. Jorgensen,et al.  Pyrogens, Endotoxins, Lal Testing and Depyrogenation , 1985 .

[13]  M Weda,et al.  Consistency of FMEA used in the validation of analytical procedures. , 2011, Journal of pharmaceutical and biomedical analysis.

[14]  Tim Sandle Environmental monitoring risk assessment , 2006 .